Pharmacological properties of 2,3-dihydro-9H-isoxazolo[3,2-b]-quinazolin-9-one (W-2429. Part 2: General pharmacological investigation.
D000779:Anesthetics, Local; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000927:Anticonvulsants; D000929:Antidepressive Agents, Tricyclic; D000996:Antitussive Agents; D002415:Cats; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D006439:Hemodynamics / Q000187:drug effects; D007555:Isoxazoles / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D010080:Oxazoles / Q000494:pharmacology*; D004856:Postural Balance / Q000187:drug effects; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D012119:Respiration / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D013276:Stomach Ulcer / Q000139:chemically induced; D013997:Time Factors
D000779:Anesthetics, Local; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D000929:Antidepressive Agents, Tricyclic; D000996:Antitussive Agents; D007555:Isoxazoles; D010080:Oxazoles; D011799:Quinazolines; D011451:Prostaglandin-Endoperoxide Synthases